An Educational Resource by
Women's Cancer Initiative - Tata Memorial Hospital
5th September 2020
Optimal management of extensive stage- SCLC
Speaker : Minish Jain
1st line Pembrolizumab in NSCLC
Speaker : Devendra Pal
1st line Nivolumab in NSCLC
Speaker : Mansi Sharma
1st line Atezolizumab in NSCLC
Speaker : Bhuvan Chugh
2nd line immunotherapy in NSCLC
Speaker : Uma Dangi
Panel discussion on 1st line IO in NSCLC
Moderator : Priya Tiwari
Immunotherapy in Stage III NSCLC/SCLC
Speaker : Akhil Kapoor
Panel discussion on role of IO in special population in lung cancer
Moderator : Anita Ramesh
Guiding the personalisation of immunotherapy in cancer through biology and biomarkers
Speaker : T P Sahoo
Guidelines to manage immune related adverse events/toxicities
Speaker : Pushpak Chirmade
Panel discussion on immunotherapy biomarkers/management of IRE`s
Moderator : Vaibhav Choudhary